TY - JOUR
T1 - Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
AU - Anker, S.D.
AU - Butler, J.
AU - Filippatos, G.
AU - Khan, M.S.
AU - Ferreira, J.P.
AU - Bocchi, E.
AU - Bohm, M.
AU - Brunner-La Rocca, H.P.
AU - Choi, D.J.
AU - Chopra, V.
AU - Chuquiure, E.
AU - Giannetti, N.
AU - Gomez-Mesa, J.E.
AU - Janssens, S.
AU - Januzzi, J.L.
AU - Gonzalez-Juanatey, J.R.
AU - Merkely, B.
AU - Nicholls, S.J.
AU - Perrone, S.V.
AU - Pina, I.L.
AU - Ponikowski, P.
AU - Senni, M.
AU - Seronde, M.F.
AU - Sim, D.
AU - Spinar, J.
AU - Squire, I.
AU - Taddei, S.
AU - Tsutsui, H.
AU - Verma, S.
AU - Vinereanu, D.
AU - Zhang, J.
AU - Jamal, W.
AU - Schnaidt, S.
AU - Schnee, J.M.
AU - Brueckmann, M.
AU - Pocock, S.J.
AU - Zannad, F.
AU - Packer, M.
AU - EMPEROR-Preserved Trial Committees and Investigators
N1 - Funding Information:
The EMPEROR‐Preserved trial was funded by the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance.
Publisher Copyright:
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Aims EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials.Methods and results EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-typenatriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 +/- 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41-50%. The mean LVEF (54 +/- 9%) was slightly lower while the median NT-proBNP [974 (499-1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists.Conclusion When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.
AB - Aims EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials.Methods and results EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-typenatriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 +/- 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41-50%. The mean LVEF (54 +/- 9%) was slightly lower while the median NT-proBNP [974 (499-1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists.Conclusion When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.
KW - Empagliflozin
KW - Heart failure with preserved ejection fraction
KW - Sodium–
KW - empagliflozin
KW - glucose co‐
KW - heart failure with preserved ejection fraction
KW - sodium–
KW - transporter 2 inhibitors
KW - SPIRONOLACTONE
KW - OUTCOMES
U2 - 10.1002/ejhf.2064
DO - 10.1002/ejhf.2064
M3 - Article
C2 - 33251670
SN - 1388-9842
VL - 22
SP - 2383
EP - 2392
JO - European journal of heart failure
JF - European journal of heart failure
IS - 12
ER -